glp-1 drugs pharmaceutical companies news 2025 Receptor Agonist Market Size & Analysis, 2026-2033 FDA takes aim at telehealth

Description

The theoretical benefit compared to the peptides is reduced receptor desensitisation and a different tolerability profile, though whether that translates to clinically meaningful differences in nausea, vomiting and discontinuation rates is still under investigation

Multiple injectable peptidic GLP-1R agonists are approved for the treatment of Type 2 diabetes mellitus (T2DM) ( 8 ), including liraglutide which is also approved for the treatment of obesity ( 9 )

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial